AM
Amarin Corporation plc
AMRN · NASDAQ
$13.63 -1.52% (-$0.21)
1M -1.52%
Market Cap $281.9M
P/E Ratio -
Div. Yield -
ROE 5.99%
Bulios Fair Price
$11.74
13.9% downside
Current Price
$13.63
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AMRN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
98 /100
Cheap P/S 1.51x
P/FCF 5.73x
P/B 0.64x
Growth
0 /100
Declining Rev. growth 16.67%
Book val. growth 8.29%
EPS growth N/A
Profitability
46 /100
Moderate Gross margin 41.58%
FCF margin 26.41%
Net margin 14.57%
Quality
4 /100
Poor ROIC 7.69%
Asset turnover 0.30x
ROE 5.99%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 3.67x
Int. coverage N/A
Stability
66 /100
Moderate Beta 0.76x
Profitable years 0
Rev. volatility 9.49%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AMRN
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Aaron D. Berg
Employees
80
Headquarters
Dublin
Upcoming events
04 NOV
Earnings
Upcoming earnings report